Non-CME ancillary events
The American Society of Regional Anesthesia and Pain Medicine (ASRA) has provided space for these non-CME ancillary events. The programs were independently produced, not subject to review by ASRA, and are not part of the scientific/educational program offered by ASRA.
Opioid-Sparing Analgesia: Why 24 Hours of Therapy Just Isn’t Enough
Friday, April 20, 7-7:45 am, Breakfast Included, Broadway South (6th floor)
Faculty: Brian Vaughan, MD
In light of the current opioid epidemic, Dr. Brian Vaughan focuses on the role of effective multimodal therapy protocols to reduce postop opioid consumption. He will review key clinical literature and examine the limitations of single shots and long-acting locals across various regional anesthesia procedures and patient populations compared to continuous peripheral nerve block pain management. Attendees will also learn considerations for both private and public practice implementation. RSVP at: Karina Gutierrez, firstname.lastname@example.org.
Challenges in Acute Pain Management and Updates in Evidence-Based Management Approaches
Friday, April 20, 12-1:00 pm, Lunch Included, Broadway North (6th floor)
Faculty: Tong J (TJ) Gan, MD
During this clinical presentation, there will be a discussion regarding current challenges for anesthesiologists in the management of surgical pain including the use of opioids, and the impact of poorly controlled pain. This will be followed by a discussion of evidence-based approaches to pain management, including a review of goals for acute pain management and recommendations for nonsteroidal anti-inflammatory drugs in multimodal analgesia and enhanced recovery after surgery (ERAS) protocols.
Outcomes, Advanced: Breakthroughs in New Pain Areas
Friday, April 20, 12-1:00 pm, Lunch Included, Broadway South (6th floor)
Faculty: Kasra Amirdelfan, MD; David Caraway, MD, PhD; Leonardo Kapural, MD, PhD; Paul Verrills, MD
Review of HF10 therapy SCS and clinical evidence in the SCS space. Physicians will discuss an overview of HF10 therapy, the only SCS therapy with superiority labeling and a paresthesia-free indication. In addition, they will share the latest long-term clincial data, real-world experiences, and tips and tricks to maximize outcomes with HF10 therapy patients.
Fast Track Spinal Anesthesia: A New Kid in Town
Saturday, April 21, 12-1 pm, Lunch Included, Broadway North (6th floor)
Faculty: Narinder Rawal, MD; Arthur Atchabahian, MD; Benjamin Fox, MD; Timo Palas, MD
CLOROTEKAL® (chloroprocaine hydrochloride) is indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing surgical procedures. Indicated procedures include those suitable for CLOROTEKAL’s short duration of action.
Current Understanding of the Peripheral and Central Components of the Pain Pathway and their Roles in Chronic Pain and Future Therapeutics
Saturday, April 21, 12-1:00 pm, Lunch Included, Broadway South (6th floor)
Faculty: Charles E. Argoff, MD; Patrick W. Mantyh, PhD
Overview of the existing evidence of the epidemiology and burden of chronic pain (CP), with a focus on the impact of aging population, the high unmet medical need, and the societal, economic, and individual burden of chronic musculoskeletal pain. An in-depth review of the current understanding of the pathophysiology of CP; the various mediators, including Nerve Growth Factor (NGF), their role in central and peripheral sensitization and, the rationale behind various pharmacological targets that are currently under investigation for CP.